Drug Approval | May 04, 2023
Indoco receives EIR for its Plant I manufacturing facility in Goa
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Subscribe To Our Newsletter & Stay Updated
